Kohl's, Rivian and AMC Entertainment fall premarket; GM and Procter & Gamble rise

  • Investing.com
  • Stock Market News
Kohl's, Rivian and AMC Entertainment fall premarket; GM and Procter & Gamble rise
Credit: © Reuters.

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Wednesday, March 1st. Please refresh for updates.

  • Kohl's (NYSE: KSS ) stock fell 7.3% after the department store chain reported a holiday-quarter loss and forecast full-year profit below expectations as customers tightened their spending.

  • Lowe’s (NYSE: LOW ) stock rose 0.3% after the home improvement retailer beat quarterly profit expectations, but offered up a disappointing full-year sales forecast, as soaring prices cause consumers to pause spending on home-related projects.

  • Rivian (NASDAQ: RIVN ) stock slumped 8.6% after the electric vehicle manufacturer forecast 2023 production well below estimates, and announced a recall of more than 12,700 vehicles.

  • Tesla (NASDAQ: TSLA ) stock rose 0.4% ahead of an investor day, and with the electric car manufacturer set to confirm a new factory in Mexico after striking a water deal.

  • AMC Entertainment (NYSE: AMC ) fell 6.9% after the cinema chain recorded a more than 15% fall in fourth-quarter revenue, adding that the box office is yet to return to pre-pandemic norms.

  • Novavax (NASDAQ: NVAX ) stock slumped 27.8% after the drugmaker said there is significant uncertainty around its 2023 revenue and announced plans to slash spending ahead of the autumn vaccination campaign.

  • Dollar Tree (NASDAQ: DLTR ) stock fell 3.2% after the discount chain forecast full-year profit below expectations as customers reined in discretionary spending.

  • Procter & Gamble (NYSE: PG ) stock rose 1.3% after UBS upgraded its stance on the consumer goods giant to ‘buy’ from ‘neutral’, saying the shares can rally nearly 20% from current levels.

  • General Motors (NYSE: GM ) stock rose 0.9% after the auto giant announced it was cutting hundreds of high-level jobs as it looks to cut costs and streamline operations.

  • Sarepta Therapeutics (NASDAQ: SRPT ) stock rose 17.1% after Morgan Stanley upgraded its stance on the biotech to ‘overweight’ from ‘equal-weight’, saying its shares can rally more than 50%.

Add Chart to Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100
Please try another search

Related Articles